ClinicalTrials.gg
CompletedNCT04889118Updated Dec 23, 2025Results posted

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

A Phase 3 interventional study of Pembrolizumab and Lenvatinib in Malignant Melanoma, sponsored by Merck Sharp & Dohme LLC. Completed at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jul 2020, registered May 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing lenvatinib in Melanoma — 3 open to participants now, 5 under way, none of them phase 3. lenvatinib · Melanoma.

Enrollment
4th of 18
131 · median 41
Started
2020
with 4 others
Phase 3
2 of 18
none open now
Registered
10th of 18
by date
Lead sponsor
4 of 18
Merck Sharp & Dohme LLC

Among the 18 studies testing lenvatinib in Melanoma, this one is the 4th largest by enrollment, is one of 5 that started in 2020, is one of 2 in phase 3, and was the 10th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 18 studies testing lenvatinib in Melanoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing lenvatinib in Melanoma, or all of them as a file.
02

Study summary

The purpose of the China Extension study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in Chinese participants with no prior systemic therapy for their advanced melanoma.

Read the detailed description

As of 03-Apr-2023, active participants, investigator, and sponsor personnel or delegate(s) involved in the treatment administration or clinical evaluation of the participants will be unblinded.

03

Conditions studied

  • Malignant Melanoma

Browse trials for

Keywords

  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death-ligand 1 (PD-L1, PDL1)
  • programmed cell death-ligand 2 (PD-L2, PDL2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed melanoma.
  • Has unresectable Stage III or Stage IV melanoma, as per American Joint Committee on Cancer guidelines, not amenable to local therapy.
  • Has been untreated for advanced or disease except as follows: a. proto-oncogene B-Raf (BRAF) V600 mutation-positive melanoma may have received standard of care targeted therapy as therapy for advanced or metastatic disease. Participants that do not have a BRAF V600 mutation but did receive BRAF or BRAF/MEKi therapy are eligible to participate in this study after discussion with the medical monitor.

    b. Prior or neoadjuvant therapy, with targeted therapy or immunotherapy (such as anti-cytotoxic T-lymphocyte-associated protein 4 [], anti-programmed cell death 1 [anti-PD-1] therapy or interferon) will only be permitted if relapse did not occur during active treatment or within 6 months of treatment discontinuation.

  • Have documentation of BRAF V600-activating mutation status or consent to BRAF V600 mutation testing during the Screening period (participants with BRAF mutation-positive melanoma as well as BRAF wild-type or unknown are eligible).
  • Has an (ECOG) performance status 0 to 1.
  • Has the presence of ≥1 by computed tomography (CT) or magnetic resonance imaging (MRI) per 1.1.
  • Provides a tumor . Participants must submit tumor sample during Screening for confirmation of adequacy of tumor tissue at a central pathology laboratory. Participants who do not submit a tumor tissue sample will not be randomized. The tumor biopsy may not be obtained from a lone target lesion. Confirmation of presence of tumor tissue is not required prior to randomization.
  • Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). If participant received major surgery or radiation therapy of >30 Gray (Gy), they must have recovered from the toxicity and/or complications from the intervention.
  • Male participants must agree to use during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.
  • Female participants must not be pregnant, not breastfeeding, and ≥1 of the following conditions applies:

    1. Not a woman of (WOCBP) OR
    2. A WOCBP who agrees to use study-approved contraception during the treatment period and for at least 120 days after the last dose of study treatment.
  • The participant (or legally acceptable representative) has provided documented for the study.
  • Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mmHg at screening and no change in antihypertensive medications within 1 week before Cycle 1 Day 1.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days before the first dose of study treatment.
  • Has a known additional that is progressing or requires active treatment.

Exceptions include early stage cancers (carcinoma in situ or Stage 1, non-ulcerated primary melanoma \<1 mm in depth with no nodal involvement) treated with curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy.

  • Has known active central nervous system and/or carcinomatous meningitis.
  • Has ocular melanoma.
  • Has known to active substances or any of their including previous hypersensitivity reaction to treatment with another monoclonal antibody.
  • Has an active disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Has an active infection requiring systemic therapy.
  • Has known history of (HIV) infection.
  • Has known history of or is positive for virus or virus infection.
  • Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
  • Has a history of active tuberculosis (Bacillus tuberculosis).
  • Has presence of gastrointestinal condition including malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib.
  • Has had a major surgery within 4 weeks prior to Cycle 1 Day 1. Adequate wound healing after major surgery must be assessed clinically and have resolved completely prior to Cycle 1 Day 1.
  • Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula.
  • Has radiographic evidence of major blood vessel invasion/infiltration.
  • Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study treatment.
  • Has clinically significant cardiovascular disease within 12 months of the first dose of study treatment including Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability.
  • Has urine protein ≥1 g/24-hour. Note: Participants with ≥2+ (≥100 mg/dL) proteinuria on urine dipstick testing (or urinalysis) will undergo 24-hour urine collection for quantitative assessment of proteinuria.
  • Prolongation of interval to >480 ms. Note: If the QTcF is prolonged to >480 ms in the presence of a pacemaker, contact the Sponsor to determine eligibility.
  • Has (LVEF) below the institutional (or local laboratory) normal range, as determined by multigated acquisition scan (MUGA) or echocardiogram.
  • Has received prior therapy in the setting. Note: Targeted therapy, , or anti-PD-1 may be allowed.
  • Has received prior systemic treatment for unresectable or metastatic melanoma other than targeted therapy as noted in Inclusion Criteria above.
  • Has received prior therapy with a monoclonal antibody, chemotherapy, or an agent or device within 4 weeks or 5 half-lives (whichever is longer) before administration of study treatment or not recovered (≤Grade 1 or at Baseline) from adverse events due to previously administered agents.

Exception to this rule would be use of denosumab, which is not excluded. Note: Participants with alopecia and ≤Grade 2 neuropathy are an exception and may enroll.

  • Has received prior radiotherapy within 2 weeks of first dose of study treatment (Cycle 1 Day 1). Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
  • Has received within 30 days before the first dose of study treatment.
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  • Has had an allogeneic tissue/solid organ transplant.
  • Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Pembrolizumab+Lenvatinib

    Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.

    Biological: Pembrolizumab · Drug: Lenvatinib

  • Active comparator
    Pembrolizumab+Placebo

    Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.

    Biological: Pembrolizumab · Drug: Placebo for lenvatinib

Interventions

  • BiologicalPembrolizumab

    IV infusion

    Also known as: MK-3475, KEYTRUDA®

  • Oral capsule

    Also known as: MK-7902, E7080, LENVIMA®

  • DrugPlacebo for lenvatinib

    Oral capsule

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    PFS is defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to approximately 30 months

  2. Overall Survival (OS)

    OS is defined as the time from date of randomization to date of death from any cause.

    Time frame: Up to approximately 30 months

Secondary outcomes

  1. Objective Response Rate (ORR) as Assessed by BICR Per RECIST 1.1

    ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to approximately 30 months

  2. Duration of Response (DOR) as Assessed by BICR Per RECIST 1.1

    For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the date of the first documented evidence of CR or PR until PD or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

    Time frame: Up to approximately 30 months

  3. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to approximately 50 months

  4. Number of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs)

    The number of participants who discontinue study treatment due to an AE will be presented.

    Time frame: Up to approximately 39 months

07

Results

Posted Jul 9, 2024

Participant flow

The China extension study enrolled 131 participants. 62 participants were randomized in the global portion for MK-7902-003 (NCT03820986) and 69 in the China extension portion

Participant flow — Overall Study
MilestonePembrolizumab+LenvatinibPembrolizumab+Placebo
Started6467
Completed00
Not completed6467
Withdrew: Death4947
Withdrew: Sponsor decision1520

Outcome measures

PrimaryProgression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

PFS is defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to approximately 30 months
Reported as:
Median · Months
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
MonthsPembrolizumab+LenvatinibPembrolizumab+Placebo
Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)6.1 (4.1 to 8.1)2.0 (2.0 to 2.1)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Pembrolizumab+Placebo · Log Rank · p = 0.0013 (One-sided p-value based on log-rank test.) · Hazard ratio (hr): 0.55 · 95% CI 0.37 to 0.81HR=Pembrolizumab + Lenvatinib vs. Pembrolizumab + Placebo
PrimaryOverall Survival (OS)

OS is defined as the time from date of randomization to date of death from any cause.

Time frame:
Up to approximately 30 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab+LenvatinibPembrolizumab+Placebo
Overall Survival (OS)19.9 (11.9 to 26.8)17.0 (12.7 to 25.7)
Statistical analysis
  • Pembrolizumab+Lenvatinib vs Pembrolizumab+Placebo · Log Rank · p = 0.3728 (One-sided p-value based on log-rank test) · Hazard ratio (hr): 0.93 · 95% CI 0.58 to 1.48HR=Pembrolizumab + Lenvatinib vs. Pembrolizumab + Placebo
SecondaryObjective Response Rate (ORR) as Assessed by BICR Per RECIST 1.1

ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to approximately 30 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) as Assessed by BICR Per RECIST 1.1
Percentage of ParticipantsPembrolizumab+LenvatinibPembrolizumab+Placebo
Objective Response Rate (ORR) as Assessed by BICR Per RECIST 1.126.6 (16.3 to 39.1)16.4 (8.5 to 27.5)
SecondaryDuration of Response (DOR) as Assessed by BICR Per RECIST 1.1

For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the date of the first documented evidence of CR or PR until PD or death from any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.

Time frame:
Up to approximately 30 months
Reported as:
Median · Months
Duration of Response (DOR) as Assessed by BICR Per RECIST 1.1
MonthsPembrolizumab+LenvatinibPembrolizumab+Placebo
Duration of Response (DOR) as Assessed by BICR Per RECIST 1.113.7 (4.2 to NA)NA (6.5 to NA)
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
Up to approximately 50 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsPembrolizumab+LenvatinibPembrolizumab+Placebo
Number of Participants With Adverse Events (AEs)6467
SecondaryNumber of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs)

The number of participants who discontinue study treatment due to an AE will be presented.

Time frame:
Up to approximately 39 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs)
ParticipantsPembrolizumab+LenvatinibPembrolizumab+Placebo
Number of Participants Who Discontinue Study Treatment Due to Adverse Events (AEs)103

Adverse events

Collected over Up to approximately 51 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab+Lenvatinib49/64 (76.6%)14/64 (21.9%)64/64 (100%)
Pembrolizumab + Placebo47/67 (70.1%)12/67 (17.9%)66/67 (98.5%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventPembrolizumab+LenvatinibPembrolizumab + Placebo
Urinary tract infectionInfections and infestations2/640/67
Acute myocardial infarctionCardiac disorders1/640/67
Cardiac arrestCardiac disorders1/640/67
ColitisGastrointestinal disorders1/640/67
PancreatitisGastrointestinal disorders1/640/67
CholecystitisHepatobiliary disorders1/640/67
GastroenteritisInfections and infestations1/640/67
PneumoniaInfections and infestations1/640/67
Upper respiratory tract infectionInfections and infestations1/640/67
Platelet count decreasedInvestigations1/640/67
Most frequent other events
Showing 10 of 73
Most frequent other events
EventPembrolizumab+LenvatinibPembrolizumab + Placebo
HypothyroidismEndocrine disorders47/6415/67
ProteinuriaRenal and urinary disorders46/6431/67
HypertriglyceridaemiaMetabolism and nutrition disorders42/6425/67
HypertensionVascular disorders41/648/67
Weight decreasedInvestigations36/6415/67
HypercholesterolaemiaMetabolism and nutrition disorders33/6413/67
Aspartate aminotransferase increasedInvestigations30/6417/67
Blood lactate dehydrogenase increasedInvestigations28/6417/67
HyperglycaemiaMetabolism and nutrition disorders27/649/67
DiarrhoeaGastrointestinal disorders26/641/67

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab+LenvatinibPembrolizumab+PlaceboTotal
Mean56.4 ± 11.757.3 ± 13.556.9 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab+LenvatinibPembrolizumab+PlaceboTotal
Female263258
Male383573
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab+LenvatinibPembrolizumab+PlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino6166127
Unknown or Not Reported314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab+LenvatinibPembrolizumab+PlaceboTotal
American Indian or Alaska Native000
Asian6467131
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

11 sites
  • Beijing Cancer Hospital (0601)
    Beijing, Beijing Municipality 100036, China
  • Fujian Provincial Cancer Hospital ( Site 0612)
    Fuzhou, Fujian 350014, China
  • Sun Yat-Sen University Cancer Center (0602)
    Guangzhou, Guangdong 510000, China
  • Henan Cancer Hospital ( Site 0610)
    Zhengzhou, Henan 450003, China
  • Nanjing Drum Tower Hospital (0609)
    Nanjing, Jiangsu 210008, China
  • The First Hospital Of Jilin University (0603)
    Changchun, Jilin 130021, China
  • Fudan University Shanghai Cancer Center ( Site 0607)
    Shanghai, Shanghai Municipality 200032, China
  • Tianjin Medical University Cancer Institute & Hospital (0606)
    Tianjin, Tianjin Municipality 300060, China
  • Yunnan Cancer Hospital (0604)
    Kunming, Yunnan 430030, China
  • Sir Run Run Shaw Hospital (0605)
    Hangzhou, Zhejiang 310018, China
  • Zhejiang Cancer Hospital ( Site 0608)
    Hangzhou, Zhejiang 310022, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jan 2023, 30 months.

Results were first posted in Jul 2024, 1 year 5 months after primary completion.

Of 64 industry-sponsored phase 3 interventional studies under Melanoma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 49. This study's 30 months is below that.

Counting every sponsor, half of 95 studies reached it within 47 months; a quarter within 30 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2021
First posted
May 17, 2021
StartActual
Jul 14, 2020
Primary completionActual
Jan 18, 2023
CompletionActual
Nov 1, 2024
Results first posted
Jul 9, 2024
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04889118
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
May 17, 2021
Start date
Jul 14, 2020
Primary completion
Jan 18, 2023
Completion
Nov 1, 2024
Results posted
Jul 9, 2024
Last update
Dec 23, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion